InSysBio announces its participation in JuliaCon Global 2026 (Conference on the Julia programming language) which is to be held from August 10-15, 2026 at Johannes Gutenberg University Mainz, Germany. Ivan Borisov, Senior Software Developer, InSysBio, and Evgeny Metelkin, Technology Director, InSysBio, will give a talk:
August 12, 12:00–12:15 (Europe/Berlin), Room 4:
Ivan comments on the talk, "Virtual Populations (VPops) are widely used in Quantitative Systems Pharmacology (QSP) to represent variability in patient responses to therapy using parameterized dynamical models. Unlike traditional modeling approaches that focus on average treatment effects, VPop methods aim to reproduce the full distribution of clinical outcomes observed in trials.
We introduce VPopMIP, a Julia package implementing a Mixed-Integer Programming (MIP) formulation for generating VPops that match clinical endpoints. In contrast to many existing approaches that require individual-level patient data, VPopMIP enables calibration to published clinical summary statistics (e.g., response rates, medians, and confidence intervals), which are more commonly available in practice.
The method formulates virtual patient selection as a constrained optimization problem that enforces agreement with multiple outcome measures across therapies.
We demonstrate the methodology using a solid tumor model with multiple efficacy endpoints across treatment regimens. The results illustrate how MIP-based selection provides an efficient way to construct clinically consistent virtual populations".
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | October 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Oct 2025 13:23
InSysBio to announce participation in BioTechX Europe 2025 with focus on AI and QSP
InSysBio announces their participation in BioTechX Europe 2025. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, and Igor Goryanin, Professor at University of Edinburgh, will host a roundtable discussion entitled, "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges"
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Oct 2025 12:13
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
InSysBio launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data to be added to InSysBio’s CYTOCON or fIVE databases for use in QSP modeling, analysis, or decision-making. The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
1.
29 Oct 2025 15:08
The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody
InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
